FDA to give Schering program priority review

Schering-Plough says the FDA will provide a priority review for sugammadex, which is being developed to reverse the effects of anesthesia used during surgery. Schering-Plough says the drug is significantly different than the meds already on the market for reversing the effects of anesthesia, saying the drug works for both mild and serious anesthesia induced by muscle relaxants. The priority review will cut the FDA's review process from 10 months to six.

- read the release for more info

ALSO: Schering-Plough plans to expand its manufacturing operations in Miami. Report

Suggested Articles

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.